Source: International Congress 2019 – Asthma biomarkers, diagnostics and risk factors
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Carpaij (Groningen, Netherlands), J. Vonk (Groningen, Netherlands), M. Nawijn (Groningen, Netherlands), H. Kerstjens (Groningen, Netherlands), G. Koppelman (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands). Externally validating the asthma remission prediction model to the Dutch asthma remission studies. 4512

Member's Comments

No comment yet.

Related content which might interest you: Association between asthma control trajectories in preschoolers and disease remission Source: Eur Respir J, 57 (5) 2001897; 10.1183/13993003.01897-2020 Year: 2021 Dyspnoea perception during clinical remission of atopic asthma Source: Eur Respir J 2002; 20: 1613 Year: 2002 Age at asthma diagnosis and probability of remission in a population-based study Source: Virtual Congress 2020 – Diagnosis and management of asthma Year: 2020 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Childhood factors associated with complete and clinical asthma remission at 25 and 49 years Source: Eur Respir J, 49 (6) 1601974; 10.1183/13993003.01974-2016 Year: 2017 Variability and lack of predictive ability of asthma end-points in clinical trials Source: Eur Respir J 2002; 20: 1102-1109 Year: 2002 Based on what parameters of clinical remission should inhaled corticosteroids be stopped in children with asthma? Source: Annual Congress 2013 –The best of paediatric asthma and allergy Year: 2013 Towards a cure for asthma Source: International Congress 2017 – The Lancet commission on asthma Year: 2017 Development of a novel prediction model for acute asthma exacerbation Source: International Congress 2018 – Asthma management Year: 2018 A predictive model of failed stepping-down of inhaled corticosteroids in adult asthmatics Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma Year: 2016 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Clinical features and functional parameters predict the probability of ACO in patients with asthma and COPD Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Pharmacoepidemiological analysis of the treatment of bronchial asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 683s Year: 2005 Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis Source: Eur Respir J 2016; 48: 1063-1073 Year: 2016 Comparative assessment of asthma control test and GINA classification in predicting asthma severity Source: Annual Congress 2007 - Airway regulation, provocation and monitoring II Year: 2007 Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005 Bronchodilator reversibility in asthma and COPD: findings from three large population studies Source: Eur Respir J, 54 (3) 1900561; 10.1183/13993003.00561-2019 Year: 2019 Mathematical model to predict the risk of future exacerbations in non-smoking patients with COPD Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016